Literature DB >> 27668789

Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors.

Murray Epstein1, Paula J Alvarez, Nancy L Reaven2, Susan E Funk, Karen J McGaughey, Melanie S Brenner, Wade Benton, Ladan Golestaneh.   

Abstract

Year:  2016        PMID： 27668789

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN： 1088-0224            Impact factor:   2.229


× No keyword cloud information.
  9 in total

1.  Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.

Authors:  Pablo E Pergola; David M Spiegel; Suzette Warren; Jinwei Yuan; Matthew R Weir
Journal:  Am J Nephrol       Date:  2017-10-11       Impact factor: 3.754

2.  The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population.

Authors:  Nihar R Desai; Pamala Reed; Paula J Alvarez; Jeanene Fogli; Steven D Woods; Mary Kay Owens
Journal:  Am Health Drug Benefits       Date:  2019-11

3.  Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.

Authors:  Nihar R Desai; Christopher G Rowan; Paula J Alvarez; Jeanene Fogli; Robert D Toto
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

Review 4.  Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia.

Authors:  Gates Colbert; Shilpa Sannapaneni; Edgar V Lerma
Journal:  Drug Healthc Patient Saf       Date:  2022-07-14

Review 5.  Patiromer: A Review in Hyperkalaemia.

Authors:  Hannah A Blair
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 2.859

6.  Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial.

Authors:  George L Bakris; Steven D Woods; Paula J Alvarez; Susan P Arthur; Rajeev Kumar
Journal:  Kidney Med       Date:  2021-03-13

7.  A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure Using a Large Administrative Claims Database.

Authors:  Dingwei Dai; Paula J Alvarez; Steven D Woods
Journal:  Clinicoecon Outcomes Res       Date:  2021-06-04

8.  Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.

Authors:  Bertram Pitt; George L Bakris; Matthew R Weir; Mason W Freeman; Mitja Lainscak; Martha R Mayo; Dahlia Garza; Rezi Zawadzki; Lance Berman; David A Bushinsky
Journal:  ESC Heart Fail       Date:  2018-05-16

9.  The burden of hyperkalemia in Germany - a real world evidence study assessing the treatment and costs of hyperkalemia.

Authors:  Jennifer Scarlet Haas; Kim-Sarah Krinke; Christopher Maas; Thomas Hardt; Isabella Barck; Sebastian Braun
Journal:  BMC Nephrol       Date:  2020-08-08       Impact factor: 2.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.